Aurora Cannabis (TSE:ACB) Raised to “Strong-Buy” at Atb Cap Markets

Aurora Cannabis (TSE:ACB) was upgraded by equities researchers at Atb Cap Markets from a “hold” rating to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

ACB has been the subject of a number of other research reports. ATB Capital cut their price target on Aurora Cannabis from C$11.00 to C$8.50 in a research note on Tuesday, December 17th. TD Securities raised Aurora Cannabis to a “strong-buy” rating in a research report on Thursday, December 12th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of C$5.85.

Aurora Cannabis Trading Down 3.7 %

TSE ACB opened at C$8.63 on Wednesday. Aurora Cannabis has a 52 week low of C$3.84 and a 52 week high of C$12.85. The business has a 50 day moving average price of C$6.08 and a 200-day moving average price of C$7.18. The company has a quick ratio of 2.48, a current ratio of 3.76 and a debt-to-equity ratio of 16.95. The company has a market cap of C$471.72 million, a price-to-earnings ratio of -13.70 and a beta of 2.71.

Aurora Cannabis (TSE:ACB) last released its quarterly earnings data on Wednesday, November 6th. The company reported C$0.05 earnings per share for the quarter, beating analysts’ consensus estimates of C($0.30) by C$0.35. Aurora Cannabis had a negative net margin of 11.53% and a negative return on equity of 6.13%. During the same period last year, the business earned ($0.70) EPS. As a group, equities analysts expect that Aurora Cannabis will post -0.22 earnings per share for the current fiscal year.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.